TAZ 表达在可切除非小细胞肺癌中的预后意义。

Prognostic significance of TAZ expression in resected non-small cell lung cancer.

机构信息

China State Key Laboratory of Respiratory Disease and Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

出版信息

J Thorac Oncol. 2012 May;7(5):799-807. doi: 10.1097/JTO.0b013e318248240b.

DOI:10.1097/JTO.0b013e318248240b

PMID:22481233

Abstract

INTRODUCTION

Transcriptional coactivator with PDZ-binding motif (TAZ) is known to bind to a variety of transcription factors to control cell differentiation and organ development. Recently, TAZ has been identified as an oncogene and has an important role in tumorigenicity of non-small cell lung cancer (NSCLC). Therefore, TAZ may present a novel target for the future diagnosis, prognosis, and therapy for lung cancer. We investigated the relationship between TAZ expression and clinicopathological parameters and determined its prognostic significance concerning survival in patients with resected NSCLC.

METHODS

TAZ expression was immunohistochemically studied in 181 consecutive patients with NSCLC and 20 cases of normal lung tissue. The association between expression of TAZ and clinicopathological parameters was evaluated. Kaplan-Meier survival analysis and Cox proportional hazards models were used to estimate the effect of TAZ expression on survival.

RESULTS

TAZ expression was observed in 121 of the 181 (66.8%) NSCLC. TAZ had nuclear and cytoplasmic expression. Clinicopathologically, TAZ expression was significantly associated with lung adenocarcinoma (p = 0. 002), poorer differentiation (p = 0.001), p-tumor, node, metastasis stage (p = 0.001), lymph node metastasis (p = 0.032), intratumoral vascular invasion (p = 0.004), pleural invasion (p = 0.003), adjuvant chemotherapy (p = 0.044), and poorer prognosis (p = 0.002). Multivariable analysis confirmed that TAZ expression increased the hazard of death after adjusting for other clinicopathological factors (hazard ratio, 2.56; 95% confidence interval, 1.39-4.66; p = 0.01). Overall survival was significantly prolonged in TAZ negative group when compared with TAZ positive group (61.8 versus 47.1 months; p < 0.0001), as was disease-free survival (44.3 versus 25.1 months; p < 0.0001). Adjuvant chemotherapy prolonged overall survival among resected NSCLC patients with TAZ positive expression (p = 0.001).

CONCLUSIONS

This study suggests that TAZ expression is a prognostic indicator of poorer survival probability for patients with resected NSCLC.

摘要

简介

转录共激活因子含有 PDZ 结合基序（TAZ），已知其可与多种转录因子结合，以控制细胞分化和器官发育。最近，TAZ 已被确定为一种癌基因，在非小细胞肺癌（NSCLC）的致瘤性中发挥重要作用。因此，TAZ 可能为未来肺癌的诊断、预后和治疗提供新的靶点。我们研究了 TAZ 表达与临床病理参数之间的关系，并确定了其在接受 NSCLC 根治性切除的患者中与生存相关的预后意义。

方法

对 181 例连续 NSCLC 患者和 20 例正常肺组织的 TAZ 表达进行免疫组化研究。评估 TAZ 表达与临床病理参数之间的关系。采用 Kaplan-Meier 生存分析和 Cox 比例风险模型估计 TAZ 表达对生存的影响。

结果

181 例 NSCLC 中有 121 例（66.8%）表达 TAZ。TAZ 有核和胞质表达。临床病理分析显示，TAZ 表达与肺腺癌（p = 0.002）、分化差（p = 0.001）、p-TNM 分期（p = 0.001）、淋巴结转移（p = 0.032）、肿瘤内血管侵犯（p = 0.004）、胸膜侵犯（p = 0.003）、辅助化疗（p = 0.044）和预后较差（p = 0.002）显著相关。多变量分析证实，在调整其他临床病理因素后，TAZ 表达增加了死亡的危险（风险比，2.56；95%置信区间，1.39-4.66；p = 0.01）。与 TAZ 阳性组相比，TAZ 阴性组的总生存时间显著延长（61.8 个月比 47.1 个月；p < 0.0001），无病生存时间也显著延长（44.3 个月比 25.1 个月；p < 0.0001）。辅助化疗可延长 TAZ 阳性表达的 NSCLC 患者的总生存时间（p = 0.001）。